Patent search ap:("AbbVie Inc.") AND inv:"Peter T. Mayer" Page 5

41.

发明申请
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF 审中-公开

公开(公告)号：US20180298016A1

公开(公告)日：2018-10-18

申请号：US15954039

申请日：2018-04-16

Applicant: AbbVie Inc.

Inventor： Aileen L. Pangan , Henrique D. Teixeira , Ayman D. Allian , Thomas B. Borchardt , Jayanthy Jayanth , Patrick J. Marroum , Fredrik Lars Nordstrom , Ahmad Y. Sheikh , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Peter T. Mayer

IPC: C07D487/14 , A61K47/38 , A61K31/4985 , A61K9/00 , A61K47/12

CPC classification number: C07D487/14 , A61K9/0053 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.

42.

发明申请
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpla]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF 有权

公开(公告)号：US20180141955A1

公开(公告)日：2018-05-24

申请号：US15857892

申请日：2017-12-29

Applicant: AbbVie Inc.

Inventor： Jayanthy JAYANTH , Patrick J. Marroum , Peter T. Mayer , Mohamed-Eslam F. Mohamed , Ahmed A. Othman

IPC: C07D487/14 , A61K47/38 , A61K31/4985 , A61K9/00 , A61K47/12

CPC classification number: C07D487/14 , A61K9/0053 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

43.

发明授权
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof 有权

公开(公告)号：US09963459B1

公开(公告)日：2018-05-08

申请号：US15857892

申请日：2017-12-29

Applicant: AbbVie Inc.

Inventor： Jayanthy Jayanth , Patrick J. Marroum , Peter T. Mayer , Mohamed-Eslam F. Mohamed , Ahmed A. Othman

IPC: A61K9/00 , A61K31/4985 , A61K47/12 , A61K47/38 , C07D487/14

CPC classification number: C07D487/14 , A61K9/0053 , A61K31/4985 , A61K47/12 , A61K47/38 , C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

44.

发明申请
Tablet Dosage Forms 审中-公开
Title translation: 片剂剂型

公开(公告)号：US20140234415A1

公开(公告)日：2014-08-21

申请号：US14184239

申请日：2014-02-19

Applicant: ABBVIE INC.

Inventor： Todd S. McDermott , Peter T. Mayer , Benjamin M. Collman , Weili Wang , Bei Chen

IPC: A61K9/24 , B29C43/20 , A61K31/7072 , A61K31/427 , A61K31/513

CPC classification number: A61K9/209 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K31/427 , A61K31/513 , A61K31/7068 , A61K31/7072 , B29C43/203 , A61K2300/00

Abstract: The present invention features tablet dosage forms comprising two or more different active ingredients. In one embodiment, a tablet dosage form of the invention comprises a first layer and a second layer, wherein the first layer comprises polymer-based solid dispersion particles having a mean particle size of no more than 200 μm.

Abstract translation: 本发明涉及包含两种或更多种不同活性成分的片剂剂型。在一个实施方案中，本发明的片剂剂型包含第一层和第二层，其中第一层包含平均粒度不超过200μm的基于聚合物的固体分散体颗粒。

45.

发明申请
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF 有权

公开(公告)号：US20250034157A1

公开(公告)日：2025-01-30

申请号：US18913645

申请日：2024-10-11

Applicant: AbbVie Inc.

Inventor： Ayman Allian , Jayanthy Jayanth , Mohamed-Eslam F. Mohamed , Mathew M. Mulhern , Fredrik Lars Nordstrom , Ahmed A. Othman , Michael J. Rozema , Lakshmi Bhagavatula , Patrick J. Marroum , Peter T. Mayer , Ahmad Y. Sheikh , Thomas B. Borchardt , Ben Klünder , Heidi S. Camp , Robert J. Padley , Jeffrey W. Voss

IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/02 , A61K47/12 , A61K47/38 , C07D487/04

Abstract: The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.

46.

发明申请
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF 有权

公开(公告)号：US20240376115A1

公开(公告)日：2024-11-14

申请号：US18776040

申请日：2024-07-17

Applicant: AbbVie Inc.

Inventor： Ayman Allian , Jayanthy Jayanth , Mohamed-Eslam F. Mohamed , Mathew M. Mulhern , Fredrik Lars Nordstrom , Ahmed A. Othman , Michael J. Rozema , Lakshmi Bhagavatula , Patrick J. Marroum , Peter T. Mayer , Ahmad Y. Sheikh , Thomas B. Borchardt , Ben Klünder

IPC: C07D487/14 , A61K9/00 , A61K31/4985 , A61K47/02 , A61K47/12 , A61K47/38 , C07D487/04

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl) pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

47.

发明授权
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof 有权

公开(公告)号：US12134621B2

公开(公告)日：2024-11-05

申请号：US18328350

申请日：2023-06-02

Applicant: AbbVie Inc.

Inventor： Jayanthy Jayanth , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Patrick J. Marroum , Peter T. Mayer , Ben Klünder

IPC: A61K31/4985 , A61K9/00 , A61K47/02 , A61K47/12 , A61K47/38 , C07D487/04 , C07D487/14

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.